Join our daily newsletter At The Bell to receive exclusive market insights
- LBT Innovations (LBT) will present data from five clinical studies featuring its APAS Independence technology at a major medical conference
- The Automated Plate Assessment System (APAS) is a platform technology designed to automate culture-plate screening and interpretation
- The presentations will feature data from several studies completed around the world
- One will also be used to demonstrate the use of the APAS technology in reading culture plates much earlier than currently recommended
- Shares in LBT Innovations are up 10.11 per cent to 9.8 cents as of 4:15 pm AEST
LBT Innovations (LBT) will present data from five clinical studies featuring its APAS Independence technology at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
The Automated Plate Assessment System (APAS) — developed in collaboration with the University of Adelaide’s Australian Institute of Machine Learning — is a platform technology designed to automate culture-plate screening and interpretation.
The presentations will feature data from studies completed by the Health Services Laboratory in the UK, SA Pathology in Australia and two from LBT’s “key opinion leader” Labor Dr Wisplinghoff in Germany.
An additional presentation will demonstrate the use of the APAS technology in reading culture plates much earlier than currently recommended.
In a statement released this morning, LBT cited the study by SA Pathology in particular, which provided the first direct comparison between APAS Independence and a total laboratory automation system. It found that APAS Independence showed improved sensitivity for the screening of MRSA culture plates after a period of 48 hours than the established Becton Dickinson Kiestra system.
While presenting at ECCMID, which will be held online from July 9 to July 12, has no direct commercial significance, LBT said it was critical for raising clinical awareness and showing the “robustness” of the technology.
“The presentation of independent clinical data at the largest global conference in our industry is extremely important as it provides reference points for customers and clinicians when evaluating the APAS Independence,” said Dr Steven Giglio, Scientific Director at LBT.
“Application of the APAS technology to early culture reads has the potential to further disrupt the current application of testing in clinical laboratories, with the potential to improve patient care through faster turnaround of results.”
Shares in LBT Innovations are up 10.11 per cent to 9.8 cents as of 4:15 pm AEST.
